Integral Health Asset Management LLC Takes Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

Integral Health Asset Management LLC bought a new stake in Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,400,000 shares of the company's stock, valued at approximately $7,392,000. Integral Health Asset Management LLC owned about 6.79% of Protara Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Protara Therapeutics by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after acquiring an additional 9,553 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Protara Therapeutics by 90.4% during the fourth quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock valued at $195,000 after buying an additional 17,572 shares during the last quarter. HBK Investments L P bought a new position in shares of Protara Therapeutics during the fourth quarter valued at about $106,000. Dimensional Fund Advisors LP bought a new position in shares of Protara Therapeutics during the fourth quarter valued at about $111,000. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Protara Therapeutics by 12.4% during the fourth quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock valued at $1,064,000 after buying an additional 22,301 shares during the last quarter. Institutional investors own 38.13% of the company's stock.

Protara Therapeutics Stock Up 2.6%

Shares of Protara Therapeutics stock traded up $0.08 during trading on Friday, reaching $3.19. 257,245 shares of the stock were exchanged, compared to its average volume of 773,221. The stock's fifty day moving average is $3.93 and its 200 day moving average is $4.13. The firm has a market cap of $123.08 million, a price-to-earnings ratio of -1.13 and a beta of 1.73. Protara Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $10.48.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.18. Equities analysts forecast that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Insiders Place Their Bets

In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total value of $96,144.72. Following the completion of the sale, the insider now directly owns 98,861 shares in the company, valued at $447,840.33. This trade represents a 17.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 12.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

TARA has been the topic of a number of recent research reports. Lifesci Capital initiated coverage on Protara Therapeutics in a research note on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price objective on the stock. Cantor Fitzgerald initiated coverage on Protara Therapeutics in a research note on Friday, March 14th. They set an "overweight" rating on the stock. Scotiabank initiated coverage on Protara Therapeutics in a research note on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Monday, April 28th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $20.40.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.